Fresenius Kabi USA has announced the availability of Acetylcysteine Solution, USP, 20% 30ml vial for inhalation (mucolytic agent) or oral administration (acetaminophen antidote) to treat lung diseases.
Acetylcysteine Solution, USP, developed by InnoPharma, is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions including chronic bronchopulmonary disease, acute bronchopulmonary disease, pulmonary complications of cystic fibrosis and post-traumatic chest conditions.
Fresenius Kabi USA president and chief executive officer John Ducker said, "The introduction of Acetylcysteine Solution further illustrates Fresenius Kabi's commitment to meeting market needs in the short term, while broadening the availability of our APP critical care products for the long term,"
Acetylcysteine Solution, USP, 20% inhalation therapy reduces the viscosity of mucus, thinning mucus secretions while oral therapy is used to prevent or lessen hepatic injury following acetaminophen overdose.
Fresenius Kabi has a licensing contract to sell, market and distribute Acetylcysteine Solution, USP, in the US, with InnoPharma.
